Online citations, reference lists, and bibliographies.
← Back to Search

Synthesis, Radiolabeling And In Vitro And In Vivo Characterization Of A Technetium-99m-labeled Alpha-M2 Peptide As A Tumor Imaging Agent.

S. Okarvi
Published 2004 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
In an effort to develop a peptide-based radiopharmaceutical for the detection of breast cancer, we have prepared an analog of alphaM2 peptide, modified to incorporate an N3S chelate system. Mercaptoacetyltriglycine (MAG)(3)-derivatized alphaM2 peptide was prepared by solid-phase synthesis and radiolabeled with (99m)Tc by an exchange method. In vitro cell-binding on human breast cancer cell lines, MDA-MB-231 and MCF-7, indicated the affinity and specificity of (99m)Tc-MAG(3)-alphaM2 toward breast cancer cells. Additionally, the radiolabeled peptide showed rapid internalization into human breast cancer cells. In vivo biodistribution in mice showed that the radiolabeled peptide cleared rapidly from the blood and most non-target tissues and was excreted significantly via the kidneys. Uptake of (99m)Tc-MAG(3)-alphaM2 in the tumor was moderate. The radiochemical and in vitro and in vivo characterization indicates that the radiolabeled peptide has certain favorable properties and it might be a useful radiopharmaceutical for the detection of breast cancer in vivo.
This paper references
Uptake of cationic technetium complexes in cultured human carcinoma cells and human xenografts.
E. Barbarics (1998)
Peptide‐based radiopharmaceuticals: Future tools for diagnostic imaging of cancers and other diseases
S. Okarvi (2004)
Acquisition protocol for breast cancer imaging with technetium-99m-labeled synthetic peptide and technetium-99m-MDP.
M. Fiorenza (1997)
99mTc-Labeled Small Peptides as Diagnostic Radiopharmaceuticals.
S. Liu (1999)
Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study
C. van de Wiele (2000)
A ticket to ride: peptide radiopharmaceuticals.
A. Fischman (1993)
Synthesis, radiolabelling and biological characteristics of a bombesin peptide analog as a tumor imaging agent.
S. Okarvi (2003)
Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids.
G. Fields (1990)
Structure-function correlation and biostability of antibody CDR-derived peptides as tumour imaging agents.
R. Hussain (1996)
Peptide radiopharmaceuticals in nuclear medicine
D. Blok (1999)
Synthesis and preclinical evaluation of technetium-99m-labeled hippurate analogues.
M. Fukuoka (1995)
Recent developments in 99Tcm-labelled peptide-based radiopharmaceuticals: an overview.
Okarvi Sm (1999)
In vitro and in vivo evaluation of new radiolabeled neurotensin(8-13) analogues with high affinity for NT1 receptors.
E. García-Garayoa (2001)
Technetium-99m labeled renal function and imaging agents: III. Synthesis of 99mTc-MAG3 and biodistribution of by-products.
W. Brandau (1988)
Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumour antibody
G. Sivolapenko (1995)
Comparison of the labelling characteristics of mercaptoacetyltriglycine (MAG3) with different S-protective groups
S. Okarvi (1997)

This paper is referenced by
Preparation and evaluation of 99mTc‐HYNIC‐D(TPPE) as a new targeted imaging probe for detection of colon cancer: Preclinical comparison with 99mTc‐HYNIC‐EPPT
F. Maleki (2020)
Synthesis, characterization and in vitro evaluation of new oxorhenium- and oxotechnetium-CCK4 derivatives as molecular imaging agents for CCK2-receptor targeting.
Sandra Dorbes (2010)
Synthesis and exploration of novel radiolabeled bombesin peptides for targeting receptor positive tumor
K. De (2017)
In vitro evaluation of cytotoxicity and cellular uptake of alternating copolymers for use as drug delivery vehicles
Michelle Miller (2009)
Preparation and evaluation of bombesin peptide derivatives as potential tumor imaging agents: effects of structure and composition of amino acid sequence on in vitro and in vivo characteristics.
S. Okarvi (2012)
Preparation and in vitro and in vivo evaluation of technetium-99m-labeled folate and methotrexate conjugates as tumor imaging agents.
S. Okarvi (2006)
Interfacial Design and Protein Engineering as Tools of Biomedical Nanotechnology in the Optimization of Protein Detecting Field Effect Transistors
T. Nicholson (2010)
Synthesis and radiobiological evaluation of a new 99mTc-labeled small peptide: 99mTc-YGGSLAK as imaging agent
K. De (2011)
Recent developments in peptide-based SPECT radiopharmaceuticals for breast tumor targeting.
S. Ahmadpour (2019)
Preclinical Evaluation of the Breast Cancer Cell-Binding Peptide, p160
V. Askoxylakis (2005)
Synthesis, radiolabeling and biological evaluation of a neutral tripeptide and its derivatives for potential nuclear medicine applications
Susmita Chandra (2009)
27 Radiochemistry and radiopharmaceuticals
D. Urch (2005)
99mTc-HYNIC-(tricine/EDDA)-FROP peptide for MCF-7 breast tumor targeting and imaging
S. Ahmadpour (2018)
"Click"-cyclized (68)Ga-labeled peptides for molecular imaging and therapy: synthesis and preliminary in vitro and in vivo evaluation in a melanoma model system.
M. E. Martin (2013)
Estudo comparativo de radiofármacos para angiogênese na detecção de melanoma
É. A. D. Oliveira (2011)
29 Metal complexes as pharmaceuticals
P. McGowan (2005)
Design, synthesis, radiolabeling and in vitro and in vivo characterization of tumor-antigen- and antibody-derived peptides for the detection of breast cancer.
S. Okarvi (2009)
Synthesis and evaluation of a technetium-99m labeled cytotoxic bombesin peptide conjugate for targeting bombesin receptor-expressing tumors.
S. Okarvi (2010)
Instituto de Pesquisas Energéticas e Nucleares
Autarquia Associada (2008)
Preparation and bioevaluation of a 99mTc-labeled chlorambucil analog as a tumor targeting agent.
D. Satpati (2009)
Semantic Scholar Logo Some data provided by SemanticScholar